Pathology: mHCC - (neo)adjuvant (NA); mHCC - 1st line (L1); mHCC - 2nd line (L2);
mHCC - (neo)adjuvant (NA) | mHCC - 1st line (L1) | mHCC - 2nd line (L2) | ||||||||||||||
IMbrave050, 2023 | NCI-2018-01106, 2022 | Wang, 2024 | IMbrave-150, 2020 | COSMIC-312, 2023 | CARES-310, 2023 | EMERALD-1, 2024 | HIMALAYA, 2022 | CheckMate 459, 2019 | CheckMate 9DW, 2024 | LEAP 002, 2023 | ORIENT-32, 2021 | RATIONALE 301, 2024 | KEYNOTE-240, 2020 | KEYNOTE-394, 2022 | ||
sintilimab | 2 | T1 | T1 | |||||||||||||
atezolizumab plus bevacizumab | 2 | T1 | T1 | |||||||||||||
pembrolizumab alone | 2 | T1 | T1 | |||||||||||||
durvalumab plus bevacizumab | 1 | T1 | ||||||||||||||
nivolumab plus ipilimumab plus SoC | 1 | T1 | ||||||||||||||
Tislelizumab | 1 | T1 | ||||||||||||||
atezolizumab plus cabozantinib | 1 | T1 | ||||||||||||||
camrelizumab based treatment | 1 | T1 | ||||||||||||||
pembrolizumab plus lenvatinib | 1 | T1 | ||||||||||||||
nivolumab plus ipilimumab | 1 | T1 | ||||||||||||||
durvalumab plus tremelimumab | 1 | T1 | ||||||||||||||
nivolumab alone | 1 | T0 | T1 | |||||||||||||
VEGF(R) inhibitor | 0 | T0 | ||||||||||||||
Standard of Care (SoC) | 0 | T0 | T0 | |||||||||||||
lenvatinib | 0 | T0 | ||||||||||||||
sorafenib | 0 | T0 | T0 | T0 | T0 | T0 | T0 | T0 | ||||||||
placebo | 0 | T0 | T0 | T0 |